Advancing the lead therapy
ADVC001 targets PSMA in metastatic prostate cancer and is in Phase 2 development. The investigational treatment uses Lead-212 to deliver radiation to tumor cells; the new financing supports its next clinical stage.
Building supply alongside the pipeline
The company is strengthening isotope supply and U.S. manufacturing to support later-stage studies and future commercial demand. Operations span North America and Australia, with global headquarters established near Boston.
Where the funding goes
- ADVC001 development toward Phase 3
- Isotope supply and U.S. manufacturing
- Additional targeted alpha therapies